Knight CNS

active

Knight Therapeutics Inc. (Knight or the “company” - https://www.gud-knight.com) is a pan-American (ex-USA) specialty pharmaceutical company headquartered in Montreal, Canada that was founded in 2014 with the objective of acquiring or in-licensing innovative pharmaceutical products. In 2019, Knight acquired a controlling stake in Grupo Biotoscana (“GBT”), a specialty pharmaceutical company with a presence across Latin America.  Knight completed the 100% acquisition in August 2020.   GBT owns manufacturing facilities for branded generic products in addition to a research and development center, all located in Argentina. With the GBT acquisition, Knight has expanded its operations in Latin America. The company is now directly present in 11 countries and has distributors in Central America and the Caribbean. The proposed IFC investment will be used to partially provide financing in connection with the acquisition of the rights to manufacture, market and sell Exelon® in Canada and Latin America (the “Territory”), as well as an exclusive license to use the intellectual property and the Exelon® trademark, from Novartis within the Territory (the “Exelon Acquisition”), as well as its commercialization in Canada and Latin America. Exelon® is indicated for the symptomatic treatment of mild to moderately severe dementia in people with Alzheimer’s disease and Parkinson’s disease.